Alnylam Pharmaceuticals, Inc. (ALNY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yvonne L. Greenstreet M.B.A., MBChB | CEO & Director | 2.15M | -- | 1963 |
| Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP | 1.05M | -- | 1968 |
| Dr. Akshay K. Vaishnaw M.D., Ph.D. | Chief Innovation Officer & Member of the Scientific Advisory Board | 1.12M | 5.9M | 1963 |
| Dr. Pushkal P. Garg M.D. | Chief Medical Officer and Executive VP of Development & Medical Affairs | 1.06M | 517.75k | 1968 |
| Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer | 971.3k | -- | 1973 |
| Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer | -- | -- | -- |
| Dr. Kevin Joseph Fitzgerald Ph.D. | Senior VP, Head of Research & Chief Scientific Officer | -- | -- | 1969 |
| Ms. Christine Regan Lindenboom | Senior VP of Investor Relations & Corporate Communications | -- | -- | 1981 |
| Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer | -- | -- | -- |
| Mr. Evan Lippman M.B.A. | Chief Corporate Development & Strategy Officer | -- | -- | -- |
Alnylam Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2,100
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Recent Events
- Apr 01, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 15, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 26, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 19, 20248-K: Corporate Changes & Voting MattersSee Full Filing